Federal Cybersecurity Readiness for Connected Medical Devices
FEDERAL DEPLOYMENT BEGINS WITH CYBERSECURITY READINESS
Federal deployment of connected medical devices requires far more than FDA authorization. Manufacturers must demonstrate cybersecurity readiness, technical documentation, lifecycle security, and operational resilience to support agency and facility review.
A connected medical device can be legally marketed in the United States and still be unready for deployment in a federal or public healthcare facility. Federal cybersecurity readiness extends far beyond basic encryption or penetration testing; reviewers evaluate the complete operating environment, including hardware, embedded software, mobile applications, gateways, servers, cloud services, interfaces, user roles, and every point where data is processed, stored, or transmitted.
Technical Security Package
Manufacturers must present a current, internally consistent security package built upon NIST SP 800-53 baseline controls.
This documentation includes a Manufacturer Disclosure Statement for Medical Device Security (MDS2), Software Bill of Materials (SBOM), operating system versions, network topology diagrams, data-flow maps, port and protocol specifications, remote-access methods, authentication, logging, and cloud dependencies.
The package must match the offered deployment configuration exactly, as a security review completed for one version or hosting architecture will not support a materially altered setup.
Authorization Boundaries and FedRAMP / GovRAMP Integration
Defining explicit system authorization boundaries is critical. Reviews must delineate what resides inside the assessed boundary versus external infrastructure, which party controls each component, and how external services affect system confidentiality, integrity, and availability.
For solutions using cloud components or SaaS platforms, achieving FedRAMP or GovRAMP (formerly StateRAMP) status—such as Core, Ready, Provisional, or Authorized verification through an accredited Third-Party Assessment Organization (3PAO)—provides verified alignment with NIST 800-53 controls.
However, while a FedRAMP or GovRAMP designation supports the security evaluation, it does not automatically authorize the manufacturer’s end-to-end medical solution or eliminate agency-specific Authority to Operate (ATO) requirements.
Continuous Monitoring and Lifecycle Security
Cybersecurity compliance persists throughout the product lifecycle. Under agency oversight and GovRAMP/FedRAMP Continuous Monitoring (ConMon) frameworks, manufacturers must demonstrate continuous risk management.
This requires defined protocols for identifying vulnerabilities, testing patches against clinical functionality, and remediating security gaps according to strict Plan of Action and Milestones (POA&M) timelines.
Manufacturers must maintain clear lifecycle plans for operating system updates, certificate renewals, and third-party software end-of-support to avoid deployment restrictions.
Facility-Level Integration and Contingency Operations
Facility-level implementation introduces localized variables, including network segmentation, wireless access, identity management, firewall rules, and clinical IT integration.
Beyond static network compliance, devices must prove resilient contingency operations. Manufacturers must document and demonstrate which clinical functions remain operational during network, cellular, or cloud outages; how data is buffered and reconciled upon reconnection; and how alarms, licensing, and access controls behave without creating unauthorized operational workarounds.